{"transactions":[{"id":732019,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2026-06-18T20:33:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":30.57,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-26-000264","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161071726000264/form4.xml","form_type":"4"}},{"id":873984,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-03T00:18:09.000Z","date":"2026-03-02","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":32.9578,"value":1647890.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $32.743 to $33.1999, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":54281,"source":{"system":"sec-edgar","filing":"0001610717-26-000078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161071726000078/form4.xml","form_type":"4"}},{"id":944408,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":21.54,"expiration_date":"2035-03-30","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944407,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":560888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":10.75,"expiration_date":"2034-09-29","underlying":"Common Stock","underlying_shares":560888},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944406,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":13.698,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":51999},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944405,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27174,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":20.2,"expiration_date":"2033-03-26","underlying":"Common Stock","underlying_shares":27174},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944404,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16499,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":16.654,"expiration_date":"2032-03-30","underlying":"Common Stock","underlying_shares":16499},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944403,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26249,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":51,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":26249},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944402,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16499,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":39.6,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":16499},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944401,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13249,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":52.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":13249},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944400,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11749,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":80,"expiration_date":"2028-03-28","underlying":"Common Stock","underlying_shares":11749},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944399,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":156,"expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944398,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7949,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":197.8,"expiration_date":"2026-03-15","underlying":"Common Stock","underlying_shares":7949},"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944397,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67498,"price":221.5,"value":14950807.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944396,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2379,"price":221.5,"value":526948.5,"ownership":{"direct":false,"nature":"By son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944395,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:16:46.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5763,"price":221.5,"value":1276504.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001478831-26-000005","document":"wk-form4_1767835003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000005/wk-form4_1767835003.xml","form_type":"4"}},{"id":944394,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2021-12-31","kind":"gift","planned":false,"acquired":true,"shares":937,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":2379,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944393,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2021-12-31","kind":"gift","planned":false,"acquired":false,"shares":1873,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":67498,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944392,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2020-12-10","kind":"other","planned":false,"acquired":false,"shares":658,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":1442,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944391,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2020-11-10","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":40.006,"value":100015.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":69371,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944390,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2020-11-10","kind":"other","planned":false,"acquired":false,"shares":2500,"price":40.006,"value":100015.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":5763,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944389,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-09-12","kind":"purchase","planned":false,"acquired":true,"shares":367,"price":135.8,"value":49838.6,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":66871,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944388,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-09-12","kind":"other","planned":false,"acquired":false,"shares":367,"price":135.8,"value":49838.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":8263,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944387,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-06-05","kind":"purchase","planned":false,"acquired":true,"shares":750,"price":118.948,"value":89211.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":66504,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944386,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-06-05","kind":"other","planned":false,"acquired":false,"shares":750,"price":118.948,"value":89211.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":8630,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944385,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-03-31","kind":"purchase","planned":false,"acquired":true,"shares":645,"price":155,"value":99975.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":65754,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944384,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2017-03-31","kind":"other","planned":false,"acquired":false,"shares":645,"price":155,"value":99975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":9380,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":944383,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T01:12:25.000Z","date":"2016-05-23","kind":"other","planned":false,"acquired":false,"shares":270,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person."}],"balance_after":10025,"source":{"system":"sec-edgar","filing":"0001478831-26-000004","document":"wk-form4_1767834742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883126000004/wk-form4_1767834742.xml","form_type":"4"}},{"id":958144,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-22","kind":"gift","planned":false,"acquired":false,"shares":5425,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction reflects a bona fide gift of the Issuer's stock to a donor-advised fund (DAF) for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution."}],"balance_after":65109,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958143,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-19","kind":"gift","planned":false,"acquired":true,"shares":10638,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."}],"balance_after":70534,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958142,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-19","kind":"gift","planned":false,"acquired":false,"shares":10638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 50 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025."}],"balance_after":10295,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958141,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-17","kind":"gift","planned":false,"acquired":true,"shares":2244,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."}],"balance_after":59896,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958140,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-17","kind":"gift","planned":false,"acquired":false,"shares":2244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."}],"balance_after":20883,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958139,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":true,"shares":33072,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."}],"balance_after":57652,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":958138,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-29T23:04:14.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":false,"shares":33072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift transfer of shares from Reporting Person to trust for no consideration."}],"balance_after":23127,"source":{"system":"sec-edgar","filing":"0001478831-25-000004","document":"wk-form4_1767049451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000147883125000004/wk-form4_1767049451.xml","form_type":"4"}},{"id":971136,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-13T00:43:05.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2285,"price":219.6,"value":501786.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for taxes on RSU vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 600 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP), representing 200 shares purchased on each of the following dates: November 20, 2024; May 20, 2025; and November 20, 2025."}],"balance_after":56199,"source":{"system":"sec-edgar","filing":"0001610618-25-000104","document":"wk-form4_1765586582.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061825000104/wk-form4_1765586582.xml","form_type":"4"}},{"id":1101033,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T20:56:47.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":21.78,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-25-000264","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161071725000264/form4.xml","form_type":"4"}},{"id":1183283,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T22:28:15.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2025."}],"balance_after":275000,"derivative":{"exercise_price":21.54,"expiration_date":"2035-03-30","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001610618-25-000028","document":"wk-form4_1743632888.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061825000028/wk-form4_1743632888.xml","form_type":"4"}},{"id":1394366,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-02T21:25:09.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":560888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of September 30, 2024."}],"balance_after":560888,"derivative":{"exercise_price":10.75,"expiration_date":"2034-09-29","underlying":"Common Stock","underlying_shares":560888},"source":{"system":"sec-edgar","filing":"0001610618-24-000133","document":"wk-form4_1727904303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061824000133/wk-form4_1727904303.xml","form_type":"4"}},{"id":1483388,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-06-11T22:26:28.000Z","date":"2024-06-07","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":13.21,"value":105680.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.05 to $13.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":24580,"source":{"system":"sec-edgar","filing":"0001628280-24-027720","document":"wk-form4_1718144781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000162828024027720/wk-form4_1718144781.xml","form_type":"4"}},{"id":1496654,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:38:25.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":36.55,"expiration_date":"2034-05-30","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-24-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161071724000276/form4.xml","form_type":"4"}},{"id":1565914,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-20T22:46:39.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":1040000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 15, 2024."}],"balance_after":1040000,"derivative":{"exercise_price":0.6849,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":1040000},"source":{"system":"sec-edgar","filing":"0001610618-24-000023","document":"wk-form4_1710974788.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061824000023/wk-form4_1710974788.xml","form_type":"4"}},{"id":1581011,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-13T01:48:29.000Z","date":"2024-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":56692,"price":0.69,"value":39117.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for taxes on RSU vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2023."}],"balance_after":1153693,"source":{"system":"sec-edgar","filing":"0001610618-24-000017","document":"wk-form4_1710294500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061824000017/wk-form4_1710294500.xml","form_type":"4"}},{"id":1775665,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.07,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775664,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":14.05,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775663,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.1,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775662,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":14.15,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775661,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.23,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775660,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.51,"expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775659,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a \"Company Stock Option\") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.61,"expiration_date":"2031-02-18","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775658,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a \"Company RSU\") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a \"Company PSU\") (the Company RSUs and the Company PSUs, collectively \"Company Equity Awards\") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the \"Equity Award Consideration\"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1775657,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T13:21:36.000Z","date":"2023-09-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. (\"Parent\"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the \"Cash Consideration\") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right  (a \"CVR Payment\") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-23-019362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000089924323019362/doc4.xml","form_type":"4"}},{"id":1812900,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-08-08T22:04:38.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.9577,"value":47885.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.93 to $0.98. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":331602,"source":{"system":"sec-edgar","filing":"0001610618-23-000081","document":"wf-form4_169153226338307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061823000081/wf-form4_169153226338307.xml","form_type":"4"}},{"id":1860432,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T20:43:29.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":16200,"derivative":{"exercise_price":25.4,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001610717-23-000110","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161071723000110/form4.xml","form_type":"4"}},{"id":1935667,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-29T21:30:23.000Z","date":"2023-03-27","kind":"grant","planned":false,"acquired":true,"shares":543500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023."}],"balance_after":543500,"derivative":{"exercise_price":1.01,"expiration_date":"2033-03-26","underlying":"Common Stock","underlying_shares":543500},"source":{"system":"sec-edgar","filing":"0001610618-23-000034","document":"wf-form4_168012541068205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061823000034/wf-form4_168012541068205.xml","form_type":"4"}},{"id":1935666,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-29T21:30:23.000Z","date":"2023-03-27","kind":"grant","planned":false,"acquired":true,"shares":271750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents time-based Restricted Stock Units (RSUs) granted on March 27, 2023. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2024, 2025, and 2026, subject to continuous service through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on May 20, 2022 and November 18, 2022."}],"balance_after":1202385,"source":{"system":"sec-edgar","filing":"0001610618-23-000034","document":"wf-form4_168012541068205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061823000034/wf-form4_168012541068205.xml","form_type":"4"}},{"id":1937837,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-27T23:03:20.000Z","date":"2023-03-27","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.0371,"value":51855.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.015 to $1.0599. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":281602,"source":{"system":"sec-edgar","filing":"0001610618-23-000026","document":"wf-form4_167995818336443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061823000026/wf-form4_167995818336443.xml","form_type":"4"}},{"id":1996337,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-23T14:27:11.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":7000,"price":1.9,"value":13300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units, pursuant to a Rule 10b5-1 trading plan."}],"balance_after":68625,"source":{"system":"sec-edgar","filing":"0000904454-23-000178","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445423000178/edgar.xml","form_type":"4"}},{"id":2025004,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T21:49:41.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 8, 2023, subject to the Reporting Person's continued service with the Issuer through the vesting date."}],"balance_after":75625,"source":{"system":"sec-edgar","filing":"0000904454-23-000111","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445423000111/edgar.xml","form_type":"4"}},{"id":2235814,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T22:22:47.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.29,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-22-012696","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000156761922012696/doc1.xml","form_type":"4"}},{"id":2308064,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-04T21:09:54.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022."}],"balance_after":330000,"derivative":{"exercise_price":0.83,"expiration_date":"2032-03-30","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001610618-22-000023","document":"wf-form4_164910656863339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061822000023/wf-form4_164910656863339.xml","form_type":"4"}},{"id":2308063,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-04T21:09:54.000Z","date":"2022-03-31","kind":"tax_withholding","acquired":false,"shares":140985,"price":0.83,"value":117017.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld for taxes on RSU vesting."}],"balance_after":922635,"source":{"system":"sec-edgar","filing":"0001610618-22-000023","document":"wf-form4_164910656863339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061822000023/wf-form4_164910656863339.xml","form_type":"4"}},{"id":2308062,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-04T21:09:54.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":408742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs granted on March 31, 2022. All RSUs are fully vested as of the grant date."}],"balance_after":1063620,"source":{"system":"sec-edgar","filing":"0001610618-22-000023","document":"wf-form4_164910656863339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061822000023/wf-form4_164910656863339.xml","form_type":"4"}},{"id":2308061,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-04T21:09:54.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022.  All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date."}],"balance_after":654878,"source":{"system":"sec-edgar","filing":"0001610618-22-000023","document":"wf-form4_164910656863339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061822000023/wf-form4_164910656863339.xml","form_type":"4"}},{"id":2385787,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-18T17:35:37.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 16, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date."}],"balance_after":55625,"source":{"system":"sec-edgar","filing":"0000904454-22-000173","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445422000173/edgar.xml","form_type":"4"}},{"id":2439994,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-01-08T01:24:39.000Z","date":"2021-12-29","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 31, 2019, the Reporting Person was granted restricted stock units totaling 60,000 shares subject to vesting upon the achievement of various milestones."}],"balance_after":20000,"derivative":{"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-002603","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919122002603/doc4.xml","form_type":"4"}},{"id":2439993,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-01-08T01:24:39.000Z","date":"2021-12-29","kind":"exercise","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted restricted stock units to vest upon the achievement of certain milestone events that occurred on December 29, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 19, 2021."}],"balance_after":489878,"source":{"system":"sec-edgar","filing":"0001209191-22-002603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919122002603/doc4.xml","form_type":"4"}},{"id":2512667,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-11-15T23:41:43.000Z","date":"2021-11-12","kind":"purchase","acquired":true,"shares":50000,"price":1.5906,"value":79530.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."}],"balance_after":465878,"source":{"system":"sec-edgar","filing":"0001610618-21-000108","document":"wf-form4_163701966996163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061821000108/wf-form4_163701966996163.xml","form_type":"4"}},{"id":2596151,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-19T20:24:31.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":10000,"price":1.7871,"value":17871.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7850 to $1.7899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."}],"balance_after":415878,"source":{"system":"sec-edgar","filing":"0001209191-21-052546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919121052546/doc4.xml","form_type":"4"}},{"id":2596150,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-19T20:24:31.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":40000,"price":1.7221,"value":68884.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6990 to $1.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2021."}],"balance_after":405878,"source":{"system":"sec-edgar","filing":"0001209191-21-052546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919121052546/doc4.xml","form_type":"4"}},{"id":2666249,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T21:05:21.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":21.66,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-21-012207","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000156761921012207/doc1.xml","form_type":"4"}},{"id":2757710,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-04-05T19:00:58.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21."}],"balance_after":361878,"source":{"system":"sec-edgar","filing":"0001610618-21-000028","document":"wf-form4_161764918481353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061821000028/wf-form4_161764918481353.xml","form_type":"4"}},{"id":2777567,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-20T01:19:27.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021."}],"balance_after":525000,"derivative":{"exercise_price":2.55,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001610618-21-000026","document":"wf-form4_161620315413253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000161061821000026/wf-form4_161620315413253.xml","form_type":"4"}},{"id":2843544,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-22T18:46:57.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":7.61,"expiration_date":"2031-02-18","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000904454-21-000238","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445421000238/edgar.xml","form_type":"4"}},{"id":2843543,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-22T18:46:57.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date."}],"balance_after":35625,"source":{"system":"sec-edgar","filing":"0000904454-21-000238","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445421000238/edgar.xml","form_type":"4"}},{"id":2983529,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-11-12T11:00:42.000Z","date":"2020-11-10","kind":"purchase","acquired":true,"shares":50000,"price":2.0003,"value":100015.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.99\nto $2.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2020."}],"balance_after":347878,"source":{"system":"sec-edgar","filing":"0001209191-20-057807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120057807/doc4.xml","form_type":"4"}},{"id":3105437,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:41:59.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.84,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-20-012374","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000156761920012374/doc1.xml","form_type":"4"}},{"id":3197891,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-23T23:17:42.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020."}],"balance_after":330000,"derivative":{"exercise_price":1.98,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001209191-20-020751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120020751/doc4.xml","form_type":"4"}},{"id":3256795,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-02-21T21:33:53.000Z","date":"2020-02-19","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 19, 2020, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":3.51,"expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000904454-20-000240","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445420000240/edgar.xml","form_type":"4"}},{"id":3256794,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-21T21:33:53.000Z","date":"2020-02-19","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 19, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date."}],"balance_after":26625,"source":{"system":"sec-edgar","filing":"0000904454-20-000240","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445420000240/edgar.xml","form_type":"4"}},{"id":3297728,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Subscription Rights (right to buy)","published_at":"2020-01-31T01:50:59.000Z","date":"2020-01-29","kind":"other","acquired":false,"shares":32283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.51,"exercise_date":"2020-01-22","expiration_date":"2020-02-10","underlying":"Common Stock","underlying_shares":32283},"source":{"system":"sec-edgar","filing":"0001209191-20-005705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120005705/doc4.xml","form_type":"4"}},{"id":3297727,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Subscription Rights (right to buy)","published_at":"2020-01-31T01:50:59.000Z","date":"2020-01-29","kind":"other","acquired":false,"shares":7558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.51,"exercise_date":"2020-01-22","expiration_date":"2020-02-10","underlying":"Common Stock","underlying_shares":7558},"source":{"system":"sec-edgar","filing":"0001209191-20-005705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120005705/doc4.xml","form_type":"4"}},{"id":3297726,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-31T01:50:59.000Z","date":"2020-01-29","kind":"other","acquired":true,"shares":32283,"price":2.51,"value":81030.33,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."}],"balance_after":257902,"source":{"system":"sec-edgar","filing":"0001209191-20-005705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120005705/doc4.xml","form_type":"4"}},{"id":3297725,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-31T01:50:59.000Z","date":"2020-01-29","kind":"other","acquired":true,"shares":7558,"price":2.51,"value":18970.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of irrevocable subscription rights to acquire shares of Common Stock after the completion of the subscription period of Issuer's rights offering, which is expected to be February 10, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2019."}],"balance_after":293878,"source":{"system":"sec-edgar","filing":"0001209191-20-005705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919120005705/doc4.xml","form_type":"4"}},{"id":3335170,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-20T00:07:44.000Z","date":"2019-09-24","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":1250,"derivative":{"exercise_price":9.15,"expiration_date":"2029-09-23","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001567619-19-023455","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000156761919023455/doc1.xml","form_type":"4"}},{"id":3405758,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-09-27T01:23:30.000Z","date":"2019-09-24","kind":"purchase","acquired":true,"shares":52500,"price":1.9067,"value":100101.75,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.84\nto $1.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set\nforth above."}],"balance_after":225619,"source":{"system":"sec-edgar","filing":"0001209191-19-050923","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119050923/doc4.xml","form_type":"4"}},{"id":3413859,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2019-09-16T21:41:28.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-049694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119049694/doc4.xml","form_type":"4"}},{"id":3413858,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-09-16T21:41:28.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2019."}],"balance_after":282320,"source":{"system":"sec-edgar","filing":"0001209191-19-049694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119049694/doc4.xml","form_type":"4"}},{"id":3581047,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-22T20:49:33.000Z","date":"2019-03-21","kind":"grant","acquired":true,"shares":265000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 21, 2019."}],"balance_after":265000,"derivative":{"exercise_price":2.61,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":265000},"source":{"system":"sec-edgar","filing":"0001209191-19-021009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119021009/doc4.xml","form_type":"4"}},{"id":3597178,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-03-13T16:54:35.000Z","date":"2019-02-26","kind":"gift","acquired":true,"shares":10670,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose."}],"balance_after":15709,"source":{"system":"sec-edgar","filing":"0001209191-19-019068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119019068/doc4.xml","form_type":"4"}},{"id":3597177,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-03-13T16:54:35.000Z","date":"2019-02-26","kind":"gift","acquired":false,"shares":21340,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose."}],"balance_after":173119,"source":{"system":"sec-edgar","filing":"0001209191-19-019068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119019068/doc4.xml","form_type":"4"}},{"id":3626580,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-28T19:48:44.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 26, 2019, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.23,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000904454-19-000291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000291/edgar.xml","form_type":"4"}},{"id":3626579,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-28T19:48:44.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 26, 2019, subject to the Reporting Person's continued service with the Issuer through the vesting date."}],"balance_after":17625,"source":{"system":"sec-edgar","filing":"0000904454-19-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000291/edgar.xml","form_type":"4"}},{"id":3646411,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-20T16:45:28.000Z","date":"2019-02-15","kind":"sale","acquired":false,"shares":3375,"price":7.14,"value":24097.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $7.09 to $7.20. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4."}],"balance_after":10125,"source":{"system":"sec-edgar","filing":"0000904454-19-000256","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000256/edgar.xml","form_type":"4"}},{"id":3679576,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2019-02-02T00:05:48.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares shall vest upon the achievement of various clinical and corporate milestones."}],"balance_after":60000,"derivative":{"expiration_date":"2022-01-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-006610","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919119006610/doc4.xml","form_type":"4"}},{"id":3743565,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-05T00:08:09.000Z","date":"2018-11-29","kind":"gift","acquired":true,"shares":4619,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By son"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose."}],"balance_after":5039,"source":{"system":"sec-edgar","filing":"0001209191-18-061058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919118061058/doc4.xml","form_type":"4"}},{"id":3743564,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-05T00:08:09.000Z","date":"2018-11-29","kind":"gift","acquired":false,"shares":9238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his sons, one of which is economically dependent on the reporting person. The reporting person disclaims beneficial ownership of the shares held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose."}],"balance_after":194459,"source":{"system":"sec-edgar","filing":"0001209191-18-061058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919118061058/doc4.xml","form_type":"4"}},{"id":3918635,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Warrant (right to buy)","published_at":"2018-05-24T21:16:35.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":250000,"price":0.125,"value":31250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrants will expire upon the earliest of (i) May 23, 2023, (ii) the date that the holder of such Warrant transfers or sells any of the shares of Common Stock purchased by such holder in the first closing of the offering (i.e. May 23, 2018), if such transfer or sale occurs prior to the date that is 120 calendar days following May 23, 2018, (iii) the taking of any short position on the Common Stock by the holder of such Warrant prior to the completion of the second closing of the offering, to be determined, and (iv) the failure by the holder of such Warrant to purchase its pro rata allocation of shares of Common Stock in the second closing of the offering, to be determined."}],"balance_after":250000,"derivative":{"exercise_price":6.81,"exercise_date":"2018-05-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-033073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919118033073/doc4.xml","form_type":"4"}},{"id":3918634,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-24T21:16:35.000Z","date":"2018-05-23","kind":"purchase","acquired":true,"shares":212766,"price":4.7,"value":1000000.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were purchased in a registered direct offering pursuant to a Subscription Agreement dated May 21, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,703 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 18, 2018."}],"balance_after":268320,"source":{"system":"sec-edgar","filing":"0001209191-18-033073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919118033073/doc4.xml","form_type":"4"}},{"id":3976413,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36795,"kind":"person","name":"Stein Jeffrey","position":1,"cik":"0001478831","reported_name":"Stein Jeffrey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-04-02T23:35:15.000Z","date":"2018-03-29","kind":"grant","acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 29, 2018."}],"balance_after":235000,"derivative":{"exercise_price":4,"expiration_date":"2028-03-28","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001209191-18-022588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478831/000120919118022588/doc4.xml","form_type":"4"}}],"next_cursor":"2018-04-02T23:35:15.000000Z,3976413"}